Skip to main content

Table 5 Cox proportional hazards univariate modeling for time to treatment failure and overall survival

From: Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

Variable

Time to treatment failure

Overall survival

 

Hazard ratio (95% CI)

P valuea

Hazard ratio (95% CI)

P valuea

Univariate modeling

   Age >50 years

0.59 (0.42–0.83)

0.0051

0.64 (0.46–0.89)

0.041

   Performance status: 0 versus 1 or 2

1.30 (0.95–1.78)

0.11

1.41 (1.03–1.94)

0.031

   ER positive

0.78 (0.56–1.08)

0.13

0.61 (0.43–0.84)

0.0029

   PR positive

0.72 (0.51–1.00)

0.53

0.71 (0.51–1.00)

0.049

   ER/PR positive

0.72 (0.51–1.00)

0.53

0.62 (0.44–0.86)

0.0048

   Number of metastatic sites: 0 to 2 versus 3+

1.72 (1.03–2.88)

0.37

1.10 (0.66–1.82)

0.72

   Disease-free interval: ≤2 years versus >2 years

0.72 (0.52–1.00)

0.49

0.81 (0.59–1.12)

0.20

   Prior adjuvant chemotherapy

0.87 (0.63–1.20)

0.39

0.93 (0.68–1.29)

0.67

   HER2 positive by CB11

1.44 (0.97–2.15)

0.68

1.34 (0.91–1.99)

0.41

   HER2 positive by FISH

1.22 (0.85–1.76)

0.29

1.24 (0.86–1.79)

0.25

   HER2 by HercepTest: 0–1 versus 2–3

1.02 (0.73–1.43)

0.90

1.04 (0.74–1.46)

0.83

   HER2 by HercepTest: 0–2 versus 3

1.34 (0.91–1.98)

0.14

1.11 (0.76–1.64)

0.59

Multivariate modeling

   Age >50 years

0.99 (0.97–1.00)

0.045

0.99 (0.97–1.00)

0.10

   ER/PR positive

1.28 (0.89–1.82)

0.18

1.55 (1.08–2.22)

0.017

   HER2 negative on HercepTest: 0–1 versus 2–3

0.97 (0.68–1.40)

0.88

0.93 (0.65–1.35)

0.71

  1. a P values were calculated using the log-rank test. CI, confidence interval; ER, estrogen receptor; FISH, fluorescence in situ hybridization; PR, progesterone receptor.